Pfizer India Shifts Slowly From Acute Care To Chronic Conditions

It is BMI's view that Pfizer India needs to enhance its strategy to further improve its financial results. Although the company outpaced some of its multinational rivals in terms of sales over the past twelve months, Pfizer India generally underperformed compared with local drugmakers. The Mumbai-based firm's share price on the Bombay Stock Exchange (BSE) has also underwhelmed. We would encourage Pfizer India to increase the promotion of its innovative products to those on middle-to-high incomes and expand its presence in rural

To read the full article, please choose one of the following options: